Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00634660
Recruitment Status : Completed
First Posted : March 13, 2008
Last Update Posted : February 1, 2017
Sponsor:
Information provided by (Responsible Party):
BioMarin Pharmaceutical

Tracking Information
First Submitted Date  ICMJE March 6, 2008
First Posted Date  ICMJE March 13, 2008
Last Update Posted Date February 1, 2017
Study Start Date  ICMJE May 2008
Actual Primary Completion Date April 2009   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 30, 2017)
• To assess the incidence of treatment-emergent adverse events of a single, subcutaneous (SC) injections of rAvPAL-PEG in subjects with PKU. [ Time Frame: 6 weeks ]
Specifically, safety was to be assessed by examining the incidence of all treatment-emergent adverse events reported during the study period and clinically significant changes in vital signs and clinical laboratory results, including development of rAvPAL-PEG antibodies.
Original Primary Outcome Measures  ICMJE Not Provided
Change History Complete list of historical versions of study NCT00634660 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: January 30, 2017)
  • • To evaluate the pharmacokinetics (PK) of single, SC injections of rAvPAL-PEG administered at escalating doses, in subjects with PKU. [ Time Frame: 6 weeks ]
    Specifically, exposure, AUC- and Cmax -dose proportionality, Tmax , λz and t1/2
  • • To evaluate the effect of different dose levels of rAvPAL-PEG on blood Phe concentrations in subjects with PKU. [ Time Frame: 6 weeks ]
    Specifically, exposure, AUC- and Cmax -dose proportionality, Tmax , λz and t1/2
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria
Official Title  ICMJE A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Subcutaneous Doses of rAvPAL-PEG in Subjects With Phenylketonuria
Brief Summary The purpose of this study is to assess the safety and tolerability of injections of rAvPAL-PEG in subjects with PKU.
Detailed Description This is a Phase 1, open-label, single-dose study in approximately 35 subjects with PKU who are 16 to 50 years old. Seven cohorts are planned, each consisting of 5 subjects; the cohorts as planned are 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. Increasing doses of rAvPAL-PEG will be assessed sequentially until the final dose is evaluated or any of the stopping criteria are reached. Subjects will each receive a single dose and then will be followed for a total of 42 days (6 weeks) with visits to the clinical research unit (CRU) as specified in the Schedule of Events Toxicity will be measured according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, v 3).
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Phenylketonuria
Intervention  ICMJE Drug: rAvPAL-PEG
rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
Study Arms  ICMJE
  • Active Comparator: 0.001 mg/kg
    One subcutaneous injection of 0.001 mg/kg of rAvPAL-PEG.
    Intervention: Drug: rAvPAL-PEG
  • Active Comparator: 0.003 mg/kg
    One subcutaneous injection of 0.003 mg/kg of rAvPAL-PEG.
    Intervention: Drug: rAvPAL-PEG
  • Active Comparator: 0.01 mg/kg
    One subcutaneous injection of 0.01 mg/kg of rAvPAL-PEG.
    Intervention: Drug: rAvPAL-PEG
  • Active Comparator: 0.03 mg/kg
    One subcutaneous injection of 0.03 mg/kg of rAvPAL-PEG.
    Intervention: Drug: rAvPAL-PEG
  • Active Comparator: 0.1 mg/kg
    One subcutaneous injection of 0.1 mg/kg of rAvPAL-PEG.
    Intervention: Drug: rAvPAL-PEG
  • Active Comparator: 0.3 mg/kg
    One subcutaneous injection of 0.3 mg/kg of rAvPAL-PEG.
    Intervention: Drug: rAvPAL-PEG
  • Active Comparator: 1.0 mg/kg
    One subcutaneous injection of 1.0 mg/kg of rAvPAL-PEG.
    Intervention: Drug: rAvPAL-PEG
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 24, 2010)
25
Original Estimated Enrollment  ICMJE
 (submitted: March 6, 2008)
35
Actual Study Completion Date  ICMJE October 2009
Actual Primary Completion Date April 2009   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of PKU with both of the following:
  • Current blood Phe concentration of ≥600 µmol/L at Screening.
  • Average blood Phe concentration of ≥600 µmol/L over the past 3 years, using available data.
  • Willing and able to provide written, signed informed consent, or, in the case of participants under the age of 18, provide written assent (if required) and written informed consent by a parent or legal guardian, after the nature of the study has been explained, and prior to any research-related procedures.
  • Willing and able to comply with all study procedures.
  • Between the ages of 16 and 50 years, inclusive.
  • Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.
  • Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
  • Stable diet with no significant modifications during the 4 weeks preceding the administration of study drug.
  • In generally good health as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and electrocardiogram (ECG) at Screening.

Exclusion Criteria:

  • Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  • Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study.
  • Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease).
  • Any condition that, in the view of the Principal Investigator (PI), places the subject at high risk of poor treatment compliance or of not completing the study.
  • Known hypersensitivity to rAvPAL PEG or its excipients.
  • Alanine aminotransferase (ALT) concentration > 2 times the upper limit of normal.
  • Creatinine above the upper limit of normal.
  • Donation of blood or plasma within 30 days prior to the administration of study drug.
  • Use of any over-the-counter (OTC) medication, including vitamins, within 7 days prior to the administration of study drug, without evaluation and approval by the Investigator.
  • Use of any prescription medication within 14 days prior to the administration of study drug without evaluation and approval by the Investigator.
  • Treatment with any drug known to affect hepatic enzyme activity, including (but not limited to) barbiturates, phenothiazines, cimetidine, or carbamazepine, within 30 days prior to study drug administration.
  • Use of any tobacco products within 60 days prior to study drug administration.
  • Positive urine screen for use of nicotine (cotinine) or drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, and opiates).
  • Positive test or has been treated for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 16 Years to 50 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00634660
Other Study ID Numbers  ICMJE PAL-001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party BioMarin Pharmaceutical
Study Sponsor  ICMJE BioMarin Pharmaceutical
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Celeste Decker, MD BioMarin Pharmaceutical
PRS Account BioMarin Pharmaceutical
Verification Date January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP